Inhibition of Wnt/beta-catenin to treat proliferative vitreoretinopathy

2022 Fiscal Year Final Research Report

• Project/Area Number: 19K09994
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 56060:Ophthalmology-related
• Research Institution: Oita University
• Principal Investigator: Kimoto Kenichi 大分大学, 医学部, 准教授 (50315339)
• Co-Investigator(Kenkyū-buntansha): 久保田 敏昭 大分大学, 医学部, 教授 (30205140) ; 赤嶺 孝祐 大分大学, 医学部, 助教 (60799435)
• Project Period (FY): 2019-04-01 – 2023-03-31
• Keywords: 増殖硝子体網膜症 / 網膜色素上皮細胞 / TGF-β / Wnt/β-catenin経路 / 細胞外マトリックス

Outline of Final Research Achievements

Proliferative vitreoretinopathy (PVR) is a serious and intractable complication following rhegmatogenous retinal detachment that can lead to blindness if left untreated. There is no effective drug, and vitrectomy is the only treatment, but many patients suffer from endless re-growth of the proliferative membrane, leading to blindness. The inversion of ICG-001, an inhibitor of the Wnt/β-catenin pathway, an intracellular signaling pathway, into the cells breaks the vicious cycle of this condition, ICG-001, an inhibitor of the Wnt/β-catenin pathway, into the cells, thereby breaking the vicious cycle of this pathology.

Free Research Field

網膜硝子体外科

Academic Significance and Societal Importance of the Research Achievements

増殖性硝子体網膜症という裂孔原性網膜剥離術後の重篤で難治な合併症は非常に難治で有効な薬物が未だ存在しない。Wnt/β-catenin経路の阻害剤であるICG-001という化合物がこの病態に非常に有効である研究結果が得られ、本疾患の病態形成のメカニズムがさらに解明された。失明を回避できるだけでなくより良い網膜剥離術後の視機能を多くの患者さんが得ることができる。